+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) - Drugs In Development, 2021

  • PDF Icon

    Report

  • 675 Pages
  • August 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5438179
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide 'Chronic Obstructive Pulmonary Disease - Drugs In Development, 2021', provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape. Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights


This report provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 31, 22, 7, 90, 22 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 3 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionChronic Obstructive Pulmonary Disease (COPD) - OverviewChronic Obstructive Pulmonary Disease (COPD) - Therapeutics DevelopmentChronic Obstructive Pulmonary Disease (COPD) - Therapeutics AssessmentChronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics DevelopmentChronic Obstructive Pulmonary Disease (COPD) - Drug ProfilesChronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
  • Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestonesh

Appendix
List of Tables
  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by 3SBio Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Acahealth Pharma and Biotech Co Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aeon Respire Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Afimmune Biopharma Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AIBIOS Co Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amgen Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apollo Therapeutics LLC, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aquilon Pharmaceuticals SA, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Arrowhead Pharmaceuticals Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Atriva Therapeutics GmbH, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AusBio Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Avidin Biotechnology Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Axolo Pharma Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bai Shuo Beijing Pharmaceutical Technology Co Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bayer AG, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by BioMarck Pharmaceuticals Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Biosion Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Biotoxtech Co Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by INVENT Pharmaceuticals Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Invion Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ionis Pharmaceuticals Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Johnson & Johnson, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Joincare Pharmaceutical Group Industry Co Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by KBP Biosciences Holdings Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kither Biotech Srl, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Korea United Pharm Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Koutif Therapeutics LLC, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kyowa Kirin Co Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Landos Biopharma Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Laurel Therapeutics, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by LTT Bio-Pharma Co Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mariposa Health Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MD Healthcare Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MDimune Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mereo Biopharma Group Plc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Meridigen Biotech Co Ltd, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Metagone Biotech Inc, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, 2021
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3SBio Inc
  • AB Science SA
  • AB2 Bio Ltd
  • Acahealth Pharma and Biotech Co Ltd
  • Aeon Respire Inc
  • Afimmune Biopharma Ltd
  • AIBIOS Co Ltd
  • AlgiPharma AS
  • Allinaire Therapeutics LLC
  • Amgen Inc
  • Angiocrine Bioscience Inc
  • Apollo Therapeutics LLC
  • Aquilon Pharmaceuticals SA
  • Aridis Pharmaceuticals Inc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atriva Therapeutics GmbH
  • AusBio Ltd
  • Avidin Biotechnology Ltd
  • Axolo Pharma Inc
  • Bai Shuo Beijing Pharmaceutical Technology Co Ltd
  • Bayer AG
  • Prous Institute for Biomedical Research SA
  • Pulmatrix Inc
  • Pulmotect Inc
  • Qu Biologics Inc
  • RAGE Biotech Pty Ltd
  • Re-Pharm Ltd
  • Regeneron Pharmaceuticals Inc
  • Renovion Inc
  • Resolys Bio Inc
  • Respiratorius AB
  • Rubedo Life Sciences Inc
  • S.Biomedics Co Ltd
  • San Rocco Therapeutics LLC
  • Santhera Pharmaceuticals Holding AG
  • Serenity Bioworks Inc
  • Shanghai KE Pharmaceutical Co Ltd
  • Silurian Pharmaceuticals Inc
  • Silver Valley Pharmaceutical Co Ltd
  • SMSbiotech Inc
  • SolAeroMed Inc
  • Sparrow Pharmaceuticals Inc
  • sterna biologicals Gmbh & Co KG
  • Sulfateq BV
  • Surrozen Inc
  • Suzhou Connect Biopharmaceuticals Ltd
  • Symmune Therapeutics LLC
  • Synovo GmbH
  • Syntrix Biosystems Inc
  • Taiho Pharmaceutical Co Ltd
  • Tetherex Pharmaceuticals Corp
  • Teva Pharmaceutical Industries Ltd
  • TFF Pharmaceuticals Inc
  • TGV-Inhalonix Inc
  • Therapeutic Solutions International Inc
  • Theratrophix LLC
  • Thirty Respiratory Ltd
  • Torrent Pharmaceuticals Ltd
  • Unity Biotechnology Inc
  • Validus Cellular Therapeutics Inc
  • Verona Pharma Plc
  • Verra Therapeutics LLC
  • Vicenna Pharmaceuticals Inc
  • vTv Therapeutics Inc
  • Zhengda Tianqing Pharmaceutical Group Co Ltd